CoChat

RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer

Kaye, Frederic J · 2002 · Oncogene

The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.

Abstract

The genetic components of the RB:CDK:cyclin:p16 tumor suppressor pathway undergo mutational and epigenetic alterations in a wide range of human cancers and serve as critical targets for inactivation by the transforming oncoproteins of several DNA tumor viruses. Lung cancer has been a useful model system for these studies as it was the first tumor to demonstrate an important role for RB in the genesis of a common adult malignancy and was also the first human cancer to demonstrate genetic evidence for a multi-component RB:p16 tumor suppressor pathway. Lung tumorigenesis, however, is a complex disease process that requires longstanding carcinogen exposure in order to acquire somatic alterations at many distinct genetic loci. Understanding the multifunctional properties of RB to regulate cell proliferation, differentiation, and apoptosis and how they relate to the sequential accumulation of other clonal gene defects will be essential in order to understand the specific patterns of gene inactivation observed in different subtypes of lung cancer and to fulfill the promise of 'molecular target' therapeutics.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1205834

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 79 references

Cited by

See all 153

Metadata

Authors
Kaye, F. J.
Affiliations
National Institutes of Health (US)
Corresponding author
Kaye, Frederic J
Venue
Oncogene
Published
2002-10-04
Volume
21
Issue
45
Pages
6908-6914
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2081412587
Cited by
153
References
80
Citations by year
2026: 2 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 2 · 2015: 5 · 2014: 13 · 2013: 5 · 2012: 4
FWCI
0.74
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
retinoblastoma protein, cyclin-dependent kinases, p16, tumor suppressor pathways, lung cancer, lung carcinogenesis, gene inactivation, epigenetic modifications, DNA tumor viruses, carcinogen exposure, targeted therapy
MeSH terms
Humans, Lung Neoplasms, Proto-Oncogene Proteins, Genes, Retinoblastoma, Gene Deletion, Carcinoma, Small Cell, Cyclin-Dependent Kinases, Genes, p16, Cyclin-Dependent Kinase 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. https://app.cochat.ai/papers/10.1038/sj.onc.1205834
The paper
Kaye, F. J. (2002). RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene. https://doi.org/10.1038/sj.onc.1205834

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.